Solfredoc RTU – sayretherapeutics

Solfredoc RTU®

Sayre Therapeutics offers a Docetaxel RTU – Ready-To-Use Injection formulation with the efficacy of conventional Docetaxel

Indication

An anti-neoplastic agent approved for the treatment of Breast cancer, Prostate cancer, Gastric cancer and Head & Neck cancer.

Strengths Available

20 mg/mL, 80 mg/4 mL, 120 mg/6 mL

Form

Solution for Injection (Ready-To-Use, no reconstitution required)

Route of Administration

Intravenous (IV) infusion